Oruka Therapeutics, Inc. (ORKA) shares jumped 21.79 percent to $84.14, gaining $15.11 on Monday, after reporting strong interim Phase 2a clinical data for its lead drug candidate in psoriasis.
The stock is currently trading at $84.14, compared to a previous close of $69.03 on the Nasdaq. It reached an intraday high of $91.00 and a low of $82.18, with trading volume of 3.72 million shares.
The company announced positive results from its EVERLAST-A trial evaluating ORKA-001, a next-generation IL-23p19 monoclonal antibody for moderate-to-severe plaque psoriasis. The data showed that 63.5 percent of treated patients achieved complete skin clearance at Week 16, with 83 percent reaching PASI 90, highlighting robust efficacy.
The stock's 52-week range is $8.91 to $91.00.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.